Sangamo Therapeutics AI Stock Analysis
Sangamo Therapeutics (0R1D) AI Stock Analysis
Sangamo Therapeutics
(LSE:0R1D)
No summary available
Sangamo Therapeutics (0R1D) vs. iShares MSCI United Kingdom ETF (EWC)
- Market Cap
- $48.47M
- Dividend Yield
- ―
- Average Volume (3M)
- 55.10K
- Price to Earnings (P/E)
- -0.2
- Beta (1Y)
- 0.45
- Revenue Growth
- -45.80%
- EPS Growth
- -0.16%
- Country
- UK
- Employees
- 142
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
Sangamo Therapeutics Business Overview & Revenue Model
Company Description
Sangamo Therapeutics, Inc., a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage...
Sangamo Therapeutics Earnings Call Summary
The call highlights meaningful clinical and regulatory progress for ST-920 (rolling BLA, FDA affirmation of 2-year confirmatory endpoint, durable long-term patient data) and continued advancement across neurology programs and platform technologies. However, material near-term risks center on capital availability and a NASDAQ delisting determination that forced a transition to the OTCQB market. Progress on regulatory and scientific fronts is balanced by significant financing and market-listing challenges that could impact execution and timing.
Q1-2026 Updates
Positive Updates
Negative Updates
Company Guidance
Sangamo said the rolling BLA for ST‑920 is in progress with the first two modules submitted, the clinical module (1‑year data) already filed, management characterizing the filing as roughly 3/5 complete and anticipating BLA completion “as early as this summer” subject to securing additional funding; the FDA agreed accelerated approval can be based on mean annualized eGFR slope at 52 weeks across all 32 dosed patients, affirmed no additional confirmatory trial is required, and indicated 104‑week (2‑year) data across those 32 patients may be used for full approval (the last patient reached the 2‑year time point around April). Management also highlighted durability and safety — four patients beyond five years with supraphysiological alpha‑Gal and 17 patients off ERT (some >3 years) — and operational progress in neurology with six sites activated for the Phase I/II STAND (ST‑503), GLP toxicology for ST‑506 completed with analysis ongoing, and MHRA alignment on key matters.
Sangamo Therapeutics Risk Analysis
Sangamo Therapeutics disclosed 62 risk factors in its most recent earnings report. Sangamo Therapeutics reported the most risks in the "Tech & Innovation" category.
Latest Risks Added
3 New RisksSangamo Therapeutics Peers Comparison
Overall Rating
CABA44Neutral
BDTX39Underperform
ELTX39Underperform
CRBU21Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 44Neutral | $276.12M | -0.90 | -106.78% | ― | ― | 43.51% | |
| 39Underperform | $84.48M | -1.93 | -43.99% | ― | -100.00% | -302.37% | |
| 39Underperform | $42.46M | -0.82 | -529.69% | ― | ― | 46.62% | |
| 21Underperform | $39.10M | -0.35 | -102.74% | ― | 1.60% | 39.34% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| GB:0R1D | Sangamo Therapeutics, Inc. | 0.11 | -0.33 | -75.46% | |
| CABA | Cabaletta Bio, Inc. | 1.28 | -1.11 | -46.44% | |
| BDTX | Black Diamond Therapeutics, Inc. | 1.47 | -2.54 | -63.34% | |
| ELTX | Elicio Therapeutics, Inc | 1.50 | -7.22 | -82.80% | |
| CRBU | Caribou Biosciences, Inc. | 0.36 | -1.53 | -80.90% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
